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Abstract: The prevalence of diet-induced obesity is increasing amongst adults and children 
worldwide, predisposing millions of people to an array of health problems that include metabolic 
syndrome, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. In this study we 
used experimental animals to investigate the effects of dietary obesity on markers of hepatic 
insulin signaling as well as structural changes in hepatocytes. Adult male Wistar rats were 
randomized and assigned to either a control group or a test group. Controls were fed standard 
laboratory pelleted diet (chow-fed), while the test group had free access to a highly-palatable 
diet (HPD). After eight weeks, the HPD-fed animals were subdivided into three subgroups and 
their diets altered as follows: HPD-to-chow, HPD with the addition of fenofibrate given by oral 
gavage for a further seven weeks, or HPD with vehicle (1% carboxymethylcellulose at 1 mL/kg 
body weight) given by oral gavage for a further seven weeks, respectively. Untreated diet-fed 
animals had significantly higher body weight, liver weight, and all measured metabolic profiles 
compared with chow-fed and treated diet-fed groups. Expression of kinases IRβ, IRS-1, AKt, 
eNOS, Shc and ERK1/2 were unaffected by obesity, while IRS-2 and P I3 kinase levels were 
significantly reduced in untreated HPD animals. Compared with chow-fed animals, steatosis 
and steatohepatitis were almost doubled in animals from untreated HPD, while removal of HPD 
and fenofibrate-treatment reduced steatosis by 40% and 80% respectively. These data suggest 
that diet-induced obesity affects intracellular insulin signaling mechanisms, namely IRS-2 and 
PI 3-kinase, leading to hepatic insulin resistance. Moreover, diet-induced obesity induces fatty 
liver, an effect which can be reversed by either removal of the source of obesity or treatment 
with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist.
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Introduction
Obesity has been associated with glucose intolerance, insulin resistance, dyslipidemia 
and cardiovascular disease.1 The liver has specifically been implicated as a primary site 
of insulin resistance observed with visceral obesity. The mechanism(s) relating visceral 
fat accumulation to hepatic insulin resistance are not well understood, but several 
  possible factors have been implicated. For example, increased release of adipokines 
such as TNF-α, resistin and adiponectin has been implicated in the   development of 
hepatic resistance.2,3 Alternatively, the “portal hypothesis” posits a high rate of lipolysis 
of visceral adipose tissue leading to increased delivery of free fatty acids (FFA) to 
the liver via the portal vein, thus contributing to increased hepatic fat accumulation 
and insulin resistance.4,5International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Chronic exposure of the liver to elevated FFA can 
promote liver gluconeogenesis,6 deplete enzymes involved in 
FFA oxidation and increase hepatic lipogenesis.7 In addition, 
elevated FFA is known to increase liver triglyceride (TG) 
content,8 and decrease insulin clearance,9 both of which are 
associated with insulin resistance. Thus, insulin signaling 
in the liver is critical in regulating glucose homeostasis 
and maintaining normal hepatic function. Furthermore, 
insulin resistance in hepatocytes leads to severe systemic 
insulin resistance and progressive hepatic dysfunction.10 
It is therefore plausible to assume that reduced levels of 
expression of insulin signaling components in the liver 
and/or inhibition of their activation may precipitate insulin 
resistance.
Patients with metabolic syndrome X (a combination 
of insulin resistance, deranged lipid profile and vascular 
dysfunction) develop non-alcoholic fatty liver disease 
(NAFLD). As obesity is closely associated with NAFLD,11,12 
it is expected that its incidence and prevalence will increase. 
Therefore, this study aims to investigate the effects of 
physiologic and pharmacologic weight reduction on liver 
morphology in diet-induced obese rats.
Methods
experimental protocol
Adult male Wistar rats (n = 40, weight 190 ± 3 g) were 
randomized and assigned to a control group (n = 10) and a 
test group (n = 30). Controls were fed standard laboratory 
pelleted diet (chow-fed), while the test group had free access 
to a highly-palatable diet (HPD). The standard chow diet 
provided 1310 KJ/100g total energy as carbohydrate 60%, 
fat 10%, and protein 30%. The HPD provided 1010 KJ/100g 
which consisted of 33% powdered chow, 33% condensed 
milk (Nestlé UK Ltd, York, UK) and 7% sucrose (Tate & 
Lyle, London, UK) by weight with the reminder being tap 
water. This provided 65% energy as carbohydrate, 19% as 
protein and 16% as fat. Chow-fed controls remained on their 
diet for 15 weeks, while after 8 weeks the HPD-fed animals 
were subdivided into three subgroups (each group contain-
ing 10 animals). In the first subgroup, the HPD was removed 
and the standard chow diet was reintroduced (diet-to-chow), 
while the second subgroup remained on the HPD and were 
given fenofibrate (fenofibrate-treated, 50 mg/kg/day) by 
oral gavage for a further seven weeks. The third subgroup 
(HPD-fed) was given vehicle (1% carboxymethylcellulose 
at 1 mL/kg body weight; Sigma, Gillingham, UK) by oral 
gavage daily for seven weeks.
After 15 weeks the rats were weighed and then killed 
by CO2 inhalation after two hours of fasting. The total body 
fat mass was measured immediately by a bioimpedance 
method using TOBEC® equipment (Biotec Instruments Ltd, 
Kimpton, UK). The gonadal and perirenal fat pads and the 
gastrocnemius muscle were dissected and weighed. The liver 
was dissected and snap-frozen in liquid nitrogen for later 
molecular and histologic analysis. Plasma was immediately 
separated by centrifugation before being frozen for later 
measurement of nonesterified free fatty acids (NEFA) and 
triglycerides (TG) and tumor necrosis factor alpha (TNFα), 
using commercially available diagnostic kits (Roche, 
Welwyn, UK, and Sigma Diagnostics, Gillingham, UK). 
All procedures were carried out according to institutional 
ethical guidelines.
experimental procedures
Western-immunoblotting technique
Western-immunoblotting technique was carried out on 
the four experimental groups (chow-fed, diet-to-chow, 
  fenofibrate and vehicle treated groups) to measure protein 
expression levels of kinases such as IR-β, IRS-1, IRS-2, 
Pl 3-kinase, Akt, eNOS, Shc and ERK1/2, which are involved 
in hepatic insulin signaling pathways.
Nonspecific binding proteins were discriminated by 
  incubating the blot with a blocking buffer (5% milk powder, 
1x phosphate buffer saline [PBS]) at room temperature for 
one hour, followed by immunoblotting with appropriate pri-
mary antibody (1:500 dilution) made up in blocking buffer, 
left overnight at 4°C. The following morning, blots were 
washed in 1 × PBS with 1% Tween and incubated with sec-
ondary antibody (1:1000), a horse-radish   peroxidase (HRP)-
linked anti-rabbit (or anti-goat, depending on the source of 
the species used for primary antibody) for one hour at room 
temperature. Proteins were detected using an enhanced 
chemiluminescence method. Positive controls were incubated 
for standardization of samples between blots, while molecular 
weight markers (Bio-Rad Laboratories Inc, Hercules, CA) 
were used for sizing of bands. Densitometry was used to 
quantify the bands obtained.
Liver triglyceride content
Triglyceride content was assessed in liver samples from 
all experimental groups: chow-fed, diet-fed with vehicle, 
  diet-  to-chow, and fenofibrate treated. Briefly, 80–100 mg 
liver tissue samples were homogenized in 500 µL dis-
tilled water using a Poltroon homogenizer (Kinematical, International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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  Lausanne, Switzerland). The homogenates were centrifuged 
for five minutes at 13,000 × g, and the supernatants were trans-
ferred to Eppendorf tubes. The TG assay was performed on the 
supernatant to detect the concentration of TG in liver tissue.
Liver histology
Tissue samples of liver were prepared for histologic 
examinations using ordinary tissue processing, and stained 
using a hematoxylin and eosin staining protocol. Ten liver 
specimens (ten animals) from each experimental group 
were interpreted by a single pathologist who was blinded to 
all data concerning the liver samples and the experimental 
groups under investigation. The liver samples were analyzed 
microscopically for the presence or absence of the following 
histologic features: steatosis, steatohepatitis, fibrosis 
and hepatocellular carcinoma. Histologic features were 
interpreted according to the schema outlined by Brunt et al.13 
Steatosis was graded on a 3-point scale: grade 1 = steatosis 
involving ,33% of hepatocytes; grade 2 = 33%–66%; 
grade 3 = .66%. Inflammation (steatohepatitis) was graded 
on a 4-point scale: grade 0 = no or negligible inflammation; 
grade 1 = mild; grade 2 = moderate; grade 3 = severe. 
Fibrosis was graded on a 5-point scale: stage 0 = no 
fibrosis; stage 1 = zone 3 perisinusoidal/perivenular fibrosis; 
stage 2 = zone 3 and periportal fibrosis; stage 3 = septal/
bridging fibrosis; stage 4 = cirrhosis.
Data interpretation and statistical analysis
For Western blotting, the data from chow-fed (control) 
  animals were expressed as 100% response, and the 
results from the other three groups were normalized and 
  subsequently expressed as the percentage of their   respective 
  controls. Data are expressed as mean ± SEM. Data have 
a normal   distribution (Shapiro Wilk W test). Statistical 
  significance was tested using Student’s t-test or repeated 
measures (ANOVA; Bonferroni t-test) or the Mann  –Whitney 
test, as appropriate. Results were considered statistically 
significant at P , 0.05. The histologic data are presented as 
percentages, each sample representing 10%.
Results
Body weight and metabolic changes
Animals given the HPD progressively gained more weight 
than their chow-fed counterparts. At the end of the study, 
untreated diet-fed (vehicle) animals were significantly 
heavier than chow-fed, diet-to-chow and fenofibrate-treated 
animals, while body weights of diet-to-chow and fenofibrate-
treated   animals were significantly (P , 0.01) lower than 
untreated diet-fed but not control chow-fed   animals (Table 1). 
  Compared with the chow-fed control group, the untreated diet-
fed group had significantly (P , 0.001) higher percentage total 
fat   levels, and epididymal perirenal fat masses.   Similarly, plasma 
levels of insulin, TG, NEFA and TNFα were   significantly 
(P , 0.001) higher in the untreated diet-fed group compared 
with the chow-fed group (Table 1). Removal of the palatable 
diet or fenofibrate   treatment   significantly reversed palatable 
diet-induced changes in fat masses and metabolic parameters 
(Table 1). There were no significant differences between 
plasma glucose levels and gastrocnemius muscle mass between 
the four experimental groups (Table 1).
Table 1 Physiological and metabolic characteristics of the four experimental groups
Chow-fed Untreated Fenofibrate  
treated
Diet-to-chow
Body weight (g)
 •  Initial  195 ± 3   196 ± 3 – –
 •  Mid study  500 ± 7   570 ± 12a  568 ± 12a  569 ± 14a
 •  Terminal  569 ± 7   699 ± 22a  589 ± 14bc  606 ± 16bc
% total fat mass 16.5 ± 1.1  23.6 ± 1.3a 19.9 ± 1.2bc 18.7 ± 1.2bc
% total lean mass 83.5 ± 1.0  76.4 ± 1.4a 80.1 ± 1.3bc 81.3 ± 1.5b
epididymal fat-pad mass (g)   5.9 ± 0.4  11.9 ± 1.1a   6.4 ± 0.7b   6.8 ± 0.6b
Perirenal fat-pad mass (g)   5.5 ± 0.2  11.3 ± 1.2a   6.3 ± 0.5b   6.7 ± 0.5b
Gastrocnemius muscle mass (g)   3.1 ± 0.1    3.2 ± 0.1   3.1 ± 0.1   3.2 ± 0.1
Plasma glucose (mM) 11.7 ± 0.5  13.8 ± 0.3 10.5 ± 0.3 12.7 ± 0.4
Plasma insulin (µg/L)   1.4 ± 0.1    3.7 ± 0.6a   1.2 ± 0.1b   1.4 ± 0.1b
Plasma triglyceride (mM) 0.76 ± 0.03  1.57 ± 0.16a 0.60 ± 0.03b 0.88 ± 0.04b
Plasma neFA (mM) 0.40 ± 0.02  0.51 ± 0.02a 0.31 ± 0.02b 0.45 ± 0.03b
Plasma TnFα (pg/mL)  608 ± 56 1047 ± 167a  532 ± 91b  660 ± 102b
Notes: Data are mean ± seM for n = 10 in each group. aP , 0.001 vs lean control; bP , 0.001 vs untreated; cP , 0.05 vs lean control.
Abbrevoations: neFA, ; TnFα, .International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Liver weight
Liver weight in untreated obese animals (vehicle) was 
  significantly elevated compared with the chow-fed group 
(control) (P , 0.01, 1.22-fold). Replacing the highly-
  palatable diet with standard laboratory chow (diet-to-chow 
group) completely restored the liver weight to the normal 
range with no significant difference in comparison to the 
chow-fed group. However, compared with chow-fed and 
vehicle groups, fenofibrate treatment produced a marked 
increase in liver weight of up to 2.13-fold (P , 0.01) 
(Figure 1).
Triglyceride content of liver
Compared with the chow-fed group, untreated obese animals 
(vehicle) had significantly (P , 0.05) higher TG levels. 
Diet-to-chow animals had liver TG levels similar to those of 
chow-fed, while TG levels in the fenofibrate-treated group 
were significantly reduced (P , 0.01) compared with the 
chow-fed group (Figure 2).
Expression of protein kinases  
of insulin signaling pathways  
in hepatocytes
•  IR-β and IRS-1: Diet had no significant effect on 
hepatocyte IR-β or IRS-1 levels while fenofibrate 
  treatment resulted in significant (P , 0.001) reduction 
in the concentration of IR-β and IRS-1 in hepatocytes 
(Figure 3).
•  IRS-2 and PI 3-kinase: Compared with chow-fed 
  controls, diet-fed obese vehicle-treated animals had 
  significantly lower levels of IRS-2 and PI 3-kinase 
expression (P , 0.05). Fenofibrate treatment further 
increased reduction in IRS-2 and PI 3-kinase levels 
(P , 0.0001) (Figure 4).
•  AKt: Although diet-induced obesity did not affect AKt 
levels, chronic withdrawal of the HPD caused a marked 
decrease in AKt protein (P , 0.05). Furthermore, 
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Figure  2  content  of  hepatic  triglycerides  (TG)  in  four  experimental  groups:   
chow-fed (C), vehicle (V), diet-to-chow (DC), and fenofibrate treated (F). 
Notes: Data represents means ± SEM for each group. There was a significant 
increase  in  the  vehicle  group’s  liver  triglyceride  levels  which  was  reversed  by 
fenofibrate treatment. *P , 0.01, **P , 0.000.
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Figure 3 Protein expression of A) Ir-β, and B) Irs-1 in rat liver. equal amounts 
(50 µg/well) of protein were separated by sDs-PAGe and immunoblotted with 
Ir-β or Irs-1 antibodies, respectively. The animal groups are: c) chow-fed lean 
control, V) vehicle group (untreated dietary obese), Dc (diet-to-chow group), and 
F) fenofibrate treated group. 
Notes:  Data  (mean  ±  seM)  are  normalized  to  that  of  the  control  group  and 
expressed as a percentage of chow fed (control) rats. *P , 0.001 versus chow-fed.
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Figure 1 Liver weight of the animals at the end of the experiment in four groups: 
chow-fed (C), vehicle (V), diet-to-chow (DC), and fenofibrate treated (F).
Notes:  Data  represents  means  ±  SEM  for  each  group.  There  were  significant 
increases in both vehicle and fenofibrate treated liver weights compared with chow-
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fenofibrate treatment induced a significant reduction 
(P , 0.000005) in AKt levels (Figure 5).
•  eNOS: Expression of eNOS protein was not affected in 
the three experimental groups: vehicle, diet-to-chow and 
fenofibrate groups. In fact, eNOS levels were similar in all 
groups with no significant difference between the groups 
(Figure 6).
•  Shc and ERK 1/2: Shc and ERK1/2 expressions were 
similar in chow-fed, diet-induced obese (vehicle) and 
diet-to-chow animals. However, compared with chow-
fed animals, the levels of both Shc and ERK1/2 were 
significantly (P , 0.005) reduced in fenofibrate-treated 
animals (Figure 7).
histologic features of liver tissue  
(non-alcoholic fatty liver disease)
The histologic slides of liver tissue of each animal were 
examined for the presence or absence of histologic 
  features of the different stages of non-alcoholic fatty liver 
  disease (Figure 8). Ten liver samples (ten animals) in each 
experimental group were analyzed microscopically.
steatosis (accumulation of fat in the liver)
Steatosis was found in 50% (grade 1steatosis) of the chow-
fed control group, while untreated obese animals (vehicle 
group) had steatosis in 80% of the total samples (40% grade 
1, 30% grade 2 and 10% grade 3). Steatosis was present in 
50% of the samples of the diet-to-chow group (40% grade 
1 and 10% grade 2). Fenofibrate-treated group had steatosis 
in only 10% of the total samples for this group (grade 2) 
(Table 2).
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Figure 4 Protein expression of A) Irs-2 and B) PI 3-kinase in rat liver. equal amounts 
(50 µg/well) of protein were separated by sDs-PAGe and immunoblotted with Irs-2 
and PI 3-kinase antibodies, respectively. The animal groups are: c) chow-fed lean 
control, V) vehicle group (untreated dietary obese), Dc) diet-to-chow group, of the 
control group and expressed as a percentage of chow fed (control) rats. 
Notes: *P , 0.05; **P , 0.0005 versus chow-fed.
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protein were separated by sDs-PAGe and immunoblotted with AKt antibody. The 
animal groups are: c) chow-fed lean control, V) vehicle group (untreated dietary 
obese), DC) diet-to-chow group, and F) fenofibrate treated group. 
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lipoprotein secretion in the fed state,14,15 as well as having 
a role in hepatocyte regeneration and growth.16 Therefore, 
the integrity of hepatic insulin signaling is important for 
the action of insulin in hepatocytes. Deficiency in protein 
expression of any components of insulin transduction may 
induce hepatic insulin resistance and subsequently may pre-
cipitate induction of systemic insulin resistance and Type II 
diabetes, while local hepatic insulin resistance may cause 
non-alcoholic fatty liver disease.
In general, protein kinase phosphorylation and   activation 
levels depend on the concentration of the expressed pro-
tein.17 Therefore, in hepatocytes, defective protein kinase 
expression may cause insulin resistance with subsequent 
induction of hepatic insulin resistance-related clinical dis-
orders, namely NAFLD. In the present study, diet-induced 
obesity did not affect the expression of insulin receptor β 
(IR-β) and insulin receptor substrate-1 (IRS-1), indicat-
ing that the detrimental effects of diet-induced obesity on 
hepatic insulin signaling is at postreceptor levels. This is in 
contrast with findings on genetically obese animals where 
reduced IR-β autophosphorylation secondary to its inhib-
ited expression in hepatocytes is a characteristic feature of 
the genetically obese   hypertensive strain.18 In fact another 
study has revealed that in genetically obese ob/ob mice, 
levels and activation of IRS-1 are reduced significantly.19 
Taken together, these reports   indicate that the molecular 
mechanism of hepatic insulin resistance in genetic obesity 
may involve modification in the early steps (IR-β and 
IRS-1 proteins) of insulin signaling, and that the amount 
of protein   expression may correlate directly with the levels 
of   phosphorylation and activation of the   protein. However, 
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Figure 7 Protein expression of A) shc and B) erK1/2 in rat liver. equal amounts 
(50 µg/well) of protein were separated by sDs-PAGe and immunoblotted with 
shc or erK 1/2 antibodies, respectively. The animal groups are: c) chow-fed lean 
control, V) vehicle group (untreated dietary obese), Dc) diet-to-chow group, and 
F) fenofibrate treated group. 
Notes:  Data  (mean  ±  seM)  are  normalized  to  that  of  the  control  group  and 
expressed as a percentage of the chow-fed (control) rats. *P , 0.01 versus chow-fed.
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Figure 8 histologic sectioning for the liver: A) normal liver, B) steatosis fatty liver 
grade one, C) steatosis fatty liver grade two and D) steatohepatitis grade one. 
Note: The arrows indicate the presence of adipocytes in each section.
steatohepatitis
All four groups of animals had some degree of steatohepatitis. 
The highest level was in diet-induced obese (vehicle) animals 
(70%, Grade 1) whilst fenofibrate-treated animals had the 
lowest levels of steatohepatitis (10%, Grade 1) (Table 3).
Fibrosis and hepatocellular carcinoma
The histologic examination of samples in all experimental 
groups showed no signs of the presence of advanced fea-
tures of NAFLD: fibrosis and hepatocellular carcinoma. 
All samples were negative for fibrosis and hepatocellular 
carcinoma.
Discussion
In the liver, insulin has a crucial role in mediating carbo-
hydrate and lipid homeostasis by stimulating glycogen 
synthesis, lipogenesis, lipoprotein synthesis, suppression 
of gluconeogenesis/glycogenolysis and very low density International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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unlike studies in genetically obese animals, our study does 
not show any role for IR-β and IRS-1 involvements in genesis 
of hepatic insulin resistance.
In the liver, IRS-2 appears to have a major role in 
regulating hepatic insulin action, whereas IRS-1 appears 
to have important functions in skeletal muscle.20,21 IRS-2 
has a major role in the growth-promoting actions of 
insulin, in suppressing gluconeogenesis and apoptosis in 
hepatocytes,22 and in acting as a regulatory point for the Pl 
3-kinase-AKt cascade in hepatocytes.22,23 In the present study, 
levels of expression of both proteins (IRS-2 and Pl 3-kinase) 
were significantly decreased in diet-induced obese animals, 
suggesting that diet-induced obesity has similar detrimental 
effects to those of genetic obesity on IRS-2 and Pl 3-kinase 
proteins in hepatocytes. The normal concentration of AKt 
protein in the hepatocytes of diet-induced obese animals 
in our study is consistent with other studies,24 which found 
unchanged levels of protein expression and slightly elevated 
phosphorylation of AKt in genetic obesity. Therefore, both 
types of obesity may have similar effects on AKt protein 
expression.
In this study, fenofibrate had a significant effect on the 
reduction of IRβ, IRS-1, IRS-2, and PI 3-kinase, which may 
suggest deterioration of insulin signaling pathways, ulti-
mately leading to worsening of insulin resistance. However, 
similar to previous reports, in this study, fenofibrate treatment 
improved insulin resistance as measured by plasma insulin 
and glucose levels. Therefore, a question arises as to what is 
the role/mechanism of fenofibrate in reducing hepatic IRβ, 
IRS-1, IRS-2, and PI 3-kinase protein expressions. To answer 
this important question, further investigations are required.
There is little information about hepatocyte eNOS 
expression in normal or diseased states. In hepatocytes, 
eNOS may regulate hepatic vasculature, regulating blood 
flow and blood cell interaction.25 In the present study, 
expression of eNOS in the liver was not affected by the 
different dietary manipulations, or by disease states (normal, 
steatosis or steatohepatitis). This finding is in agreement with 
others, demonstrating that the expression of eNOS protein 
and its activity in hepatocytes is not changed in chronic 
liver disorders such as alcoholic cirrhosis, viral hepatitis, 
cholestasis, and fulminant liver failure.26 The normal 
expression of the MAP-kinase pathway is a crucial factor 
in mediating the mitogenic response of insulin. A defect 
in Pl 3-kinase may overactivate the MAP-kinase pathway, 
altering insulin response. In the present study, diet-induced 
obesity did not alter the expression of two important protein 
kinases (Shc and ERK 1/2) in the MAP-kinase pathway, 
despite significant protein deficiencies in the Pl 3-kinase 
pathway in hepatocytes. Interestingly, in the present study, 
the effect of palatable-diet removal on expression of AKt 
protein in hepatocytes was similar to its affect on AKt in 
the aorta reported previously.27 Moreover, this reduction in 
AKt expression in hepatocytes may be related to the sharp 
decrease in calorie intake. A similar study demonstrated that 
moderate calorie restriction for 20 days induced a decrease 
in AKt levels,28 suggesting that caloric intake may affect 
AKt protein levels which in turn may alter insulin response 
in vasculature and hepatocytes.
Fatty liver (steatosis), the first stage of NAFLD, was appar-
ent in all experimental groups in our study. Histologic section-
ing of liver samples of diet-induced obese animals showed 
a considerable amount of fat droplets, which was further 
confirmed by a significant elevation of triglyceride content 
of liver samples. Steatohepatitis (inflammation of the liver), 
the second stage of NAFLD, in untreated obese animals 
Table 2 Total percentage of hepatic change (steatosis) in stage 1 of non-alcoholic fatty liver disease in the four experimental groups
Grade Chow-fed Vehicle Diet-to-chow Fenofibrate
steatosis (fatty change in the liver) 0 (negative samples) 50% 20% 50% 90%
1 50% 40% 40% –
2 – 30% 10% 10%
3 – 10% – –
Total % of fatty change in each group 50% 80% 50% 10%
Table 3 Percentage of hepatic inflammation in stage II of non-alcoholic fatty liver disease in the four experimental groups
Grade Chow-fed Vehicle Diet-to-chow Fenofibrate
Hepatic inflammation 0 (negative samples) 60% 30% 70% 90%
1 40% 70% 30% 10%
2 – – – –
3 – – – –
Total % of inflammation in each group 40% 70% 30% 10%International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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was also confirmed by the histologic sectioning of the liver, 
indicating that steatosis was induced as a result of increasing 
influx of lipid into the liver29 in obese animals. Simple ste-
atosis might have also progressed into   steatohepatitis due to 
increased secretion of inflammatory   markers from adipose 
tissue, which include TNF-α30 and CRP31. In the presence of 
hepatic insulin resistance, where the Pl 3-kinase pathway is 
inhibited and MAP-kinase (ERK1/2) is overactivated, liver 
disease may progress further. Previous studies have shown 
that regenerative response to liver injury is impaired in ob/ob 
obese mice with fatty livers,32 providing further support for 
the concept that inhibited regeneration contributes to disease 
progression in NAFLD. A study by Yang et al33 indicated 
that fatty hepatocytes in ob/ob mice become trapped in 
G1, the prereplicative phase of the cell cycle. However, the 
coordinated activation of the oxidant-sensitive, stress-, and 
mitogen-activated protein kinase   cascades, which normally 
occurs early in G1
34 does not occur in fatty hepatocytes, which 
have adapted to a state of chronic oxidant stress.33 In fact, 
in fatty liver, the activation of the mitogen-activated kinase, 
ERK1/2, is enhanced, with abolishment of the induction 
of the stress-activated kinase JNK. Therefore, fatty ob/ob 
hepatocytes fail to   proliferate despite robust ERK activation 
when JNK induction is abolished.35
A key feature in the molecular pathogenesis of liver 
fibrosis is the maintenance of the activated hepatic stellate cell 
phenotype by both proliferation and inhibition of apoptosis. 
Another study has demonstrated that leptin is a potent hepatic 
stellate cell mitogen and dramatically inhibits stellate cell 
apoptosis via ERK1/2 and AKt kinases.36 We and others have 
previously reported elevated plasma leptin concentration in 
diet-induced obese animals,37 a finding which suggests the 
implication of leptin and ERK1/2 in NAFLD progression.
Lifestyle modification of diet-induced obesity, repre-
sented in the present study by chronic withdrawal of HPD 
(diet-to-chow group) retarded the progression of NAFLD 
and improved the histologic features of this disease to levels 
similar to those of chow-fed animals. The positive impact 
of physiologic weight loss on liver pathophysiology has 
been suggested since the early 1990s. Studies in human 
subjects have shown that weight loss and maintenance of 
weight loss in overweight patients with liver disease would 
result in improvement of liver function and serum insulin 
levels.38,39 Indeed our study provides clear evidence that both 
physiologic and pharmacologic weight loss would improve 
liver histology and function. Moreover, the pharmacologic 
intervention (fenofibrate therapy) further improved histologic 
features to levels better than that of the chow-fed group. 
Interestingly, improvements in histologic features were 
paralleled with similar improvement in three detrimental 
factors associated with diet-induced obesity: TG content of 
the liver; plasma concentration of TNF-α; and total body 
weight, suggesting these have a role in initiating and inducing 
the different histologic features of NAFLD. Similar studies 
using a mouse model of non-alcoholic steatohepatitis have 
reported that peroxisome proliferator-activated receptor alpha 
(PPARα) agonists significantly improve hepatic steatosis, 
while PPARα (-/-) mice fed with methionine and choline 
deficient diet developed more severe steatohepatitis than 
the wild type mice,39,40 indicating a central role for PPARα 
receptors in hepatic pathophysiology.
Overall, this study indicates that diet-induced obesity 
results in hepatic insulin resistance, possibly by affecting 
expression and activation of insulin signaling proteins. 
Moreover, dietary obesity affects liver histology, leading to 
the development of NAFLD. Development of NAFLD may 
be associated with accumulation of triglycerides in the liver 
and/or changes in the hepatic insulin signaling pathway. 
These diet-induced detrimental effects on the liver can be 
attenuated and perhaps improved by both physiologic and 
pharmacologic weight reduction using PPARα agonists. 
However, it is important to conduct further research to deter-
mine if other weight-reducing pharmacologic agents would 
have beneficial effects on liver physiology.
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